Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-ADOLESCENTS-2 tirzepatide vs placebo in adolescents with obesity
2023-507655-30-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Tirzepatide once weekly with Placebo once weekly (2 arms). Primary endpoints: Percent change from baseline in body mass index (BMI) and Composite improvement in weight-related comorbidities. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2023-507655-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507655-30-00.